InsiderTrades.com logo
Jon Congleton net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jon Congleton Biography and Net Worth

CEO of Mineralys Therapeutics

Jon Congleton has served as our Chief Executive Officer and as a member of our Board since November 2020. Prior to joining us, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries, Ltd. (Teva) where, over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva’s Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.

What is Jon Congleton's net worth?

The estimated net worth of Jon Congleton is at least $11.50 million as of April 11th, 2025. Mr. Congleton owns 862,289 shares of Mineralys Therapeutics stock worth more than $11,502,935 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Congleton may own. Additionally, Mr. Congleton receives a salary of $775,770.00 as CEO at Mineralys Therapeutics. Learn More about Jon Congleton's net worth.

How old is Jon Congleton?

Mr. Congleton is currently 61 years old. There are 3 older executives and no younger executives at Mineralys Therapeutics. Learn More on Jon Congleton's age.

What is Jon Congleton's salary?

As the CEO of Mineralys Therapeutics, Inc., Mr. Congleton earns $775,770.00 per year. Learn More on Jon Congleton's salary.

How do I contact Jon Congleton?

The corporate mailing address for Mr. Congleton and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at investorrelations@mineralystx.com. Learn More on Jon Congleton's contact information.

Has Jon Congleton been buying or selling shares of Mineralys Therapeutics?

In the last ninety days, Jon Congleton has sold $186,738.61 of Mineralys Therapeutics stock. Most recently, Jon Congleton sold 15,319 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.19, for a transaction totalling $186,738.61. Following the completion of the sale, the chief executive officer now directly owns 862,289 shares of the company's stock, valued at $10,511,302.91. Learn More on Jon Congleton's trading history.

Who are Mineralys Therapeutics' active insiders?

Mineralys Therapeutics' insider roster includes Jon Congleton (CEO), Adam Levy (Chief Financial Officer), and David Rodman (Chief Medical Officer). Learn More on Mineralys Therapeutics' active insiders.

Are insiders buying or selling shares of Mineralys Therapeutics?

In the last twelve months, Mineralys Therapeutics insiders bought shares 2 times. They purchased a total of 1,896,296 shares worth more than $25,599,996.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 880,592 shares worth more than $11,566,301.71. The most recent insider tranaction occured on April, 14th when insider David Malcom Rodman sold 11,366 shares worth more than $165,147.98. Insiders at Mineralys Therapeutics own 33.2% of the company. Learn More about insider trades at Mineralys Therapeutics.

Information on this page was last updated on 4/14/2025.

Jon Congleton Insider Trading History at Mineralys Therapeutics

See Full Table

Jon Congleton Buying and Selling Activity at Mineralys Therapeutics

This chart shows Jon Congleton's buying and selling at Mineralys Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$187ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Mineralys Therapeutics Company Overview

Mineralys Therapeutics logo
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $13.34
Low: $12.90
High: $13.97

50 Day Range

MA: $12.92
Low: $8.76
High: $16.87

2 Week Range

Now: $13.34
Low: $8.24
High: $18.38

Volume

822,303 shs

Average Volume

426,510 shs

Market Capitalization

$865.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A